Abstract
A comparison of disease-free survivals after various types of hemotopoietic transplants, suggest that alloreactive T-cells are important in preventing relapse after transplant. For example, the recurrence rate for AML is about 60% after a transplant from an identical twin donor but only 15% after an HLA-matched sibling donor transplant. This allo-immune-mediated anti-tumor effect has been named graft-versus-tumor (GvT) effect or more specifically graft-versus-leukemia (GvL) effect. The increased incidence of relapse post transplant if T-lymphocytes are removed from donor marrow has led to the conclusion that T-cells are the most important component mediating a GvT/GvL effect. This notion is supported by the observation that infusion of T-cells from the transplant donor can reinduce remissions in patients who have relapsed after allogeneic transplantation. It may not be surprising, therefore, that acute or chronic GVHD further augment the GvT effect.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Benyunes MC, Higuchi C, York A, Lindgren C, Thompson JA, Buckner CD, Fefer A (1995) Immunotherapy with interleukin 2 with or without lymphokine activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial. Bone Marrow Transplant 16:283
Choudhury A, Gajewski JL, Liang JC, Popat U, Claxton DF, Kliche KO, Andreef M, Champlin RE (1997) Use of leukemic dendritic cells for the generation of antileukemic cellular cy-totoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 89:1133
Faber LM, van Luxemburg-Heijs SAP, Rijnbeek M, Willemze R, Falkenburg JHF (1996) Minor histocompatibility antigen-specific, leukemia-reactive cytotoxic T cell clones can be generated in vitro without in vivo priming using chronic myeloid leukemia cells as stimulators in the presence of a-interferon. Biol Blood Marrow Transplant 2:31
Heslop HE, Ng CYC, Li C, Smith CA, Loftin SK, Krance RA, Brenner MK, Rooney CM (1996) Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nature Med 2:551
Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, Rimm AA, Ringden O, Rozman C, Speck B, Truitt RL, Zwaan FE, Bortin MM (1990) Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75:555
Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R (1996) Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med 2:51
Klingemann H-G, Eaves CJ, Barnett MJ, Eaves AC, Hogge DE, Nantel SH, Reece E, Shepherd JD, Sutherland HJ, Phillips GL (1994) Transplantation of patients with high risk acute myeloid leukemia in first remission with autologous marrow cultured in interleukin-2 followed by interleukin-2 administration. Bone Marrow Transplant 14:389
Klingemann H-G, Grigg AP, Wilkie-Boyd K, Barnett MJ, Eaves AC, Reece DE, Shepherd JD, Phillips GL (1991) Treatment with recombinant interferon (α-2b) early after bone marrow transplantation in patients at high risk for relapse. Blood 78:3306
Klingemann H-G, Wong E, Maki G (1996) A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood. Biol Blood Marrow Transplant 2:68
Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Niederwieser D, van Rhee F, Mittermueller J, de Witte T, Holler E, Ansari H (1995) Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86:2041
Kühr T, Dougherty GJ, Klingemann H-G (1994) Transfer of the tumor necrosis factor α gene into hematopoietic progenitor cells as a model for site-specific cytokine delivery after marrow transplantation. Blood 84:2966
Kwak LW, Taub DD, Duffey PL, Bensinger WI, Bryant EM, Reynolds CW, Longo DL (1995) Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet 345:1016
Lister J, Donnenberg AD, deMagalhaes-Silverman M, Pincus SM, Bloom EJ, Elder EM, Ball ED, Whiteside TL (1995) Autologous peripheral blood stem cell transplantation and adoptive immunotherapy with activated natural killer cells in the immediate posttransplant period. Clin Cancer Res 1:607
Meloni G, Foa R, Vignetti M, Guarini A, Fenu S, Tosti S, Tos AG, Mandelli F (1994) Interleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia. Blood 84:2158
Meyers JD, Flournoy N, Sanders JE, McGuffin RW, Newton BA, Fisher LD, Lum LG, Appelbaum FR, Doney K, Sullivan KM, Storb R, Buckner CD, Thomas ED (1987) Prophylactic use of human leukocyte interferon after allogeneic marrow transplantation. Ann Intern Med 107:809
Robinson N, Sanders JE, Benyunes MC, Beach K, Lindgren C, Thompson JA, Appelbaum FR, Fefer A (1996) Phase I trial of interleukin-2 after unmodified HLA-matched sibling bone marrow transplantation for children with acute leukemia. Blood 87:1249
Weiden PL, Flournoy N, Thomas ED, Prentice R, Fefer A, Buckner CD, Storb R (1979) Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 300:1068
Rights and permissions
Copyright information
© 1999 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Klingemann, HG. (1999). Prevention and Treatment of Relapse. In: A Guide to Blood and Marrow Transplantation. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-18248-8_11
Download citation
DOI: https://doi.org/10.1007/978-3-642-18248-8_11
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-62122-2
Online ISBN: 978-3-642-18248-8
eBook Packages: Springer Book Archive